References
- Bonnie RJ, Ford MA, Phillips JK, editors. Pain management and the opioid epidemic: balancing societal and individual benefits and risks of prescription opioid use. Washington, DC: National Academies Press; 2017.
- Cicero TJ, Ellis MS, Harney J.Shifting patterns of prescription opioid and heroin abuse in the United States. N Engl J Med. 2015;373:1789–90.doi:10.1056/NEJMc1505541.
- Jones CM.Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers—United States, 2002-2004 and 2008-2010. Drug Alc Dependence. 2013;132:95–100.doi:10.1016/j.drugalcdep.2013.01.007.
- Pardo B, Taylor J, Caulkins JP, Kilmer B, Reuter P, Stein BD. The future of fentanyl and other synthetic drugs. RAND Corporation, 265 pp; 2019. Accessed 22 Apr 2020. https://www.rand.org/content/dam/rand/pubs/research_reports/RR3100/RR3117/RAND_RR3117.pdf
- Jones CM, Campopiano M, Baldwin G, McCance-Katz E.National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105:e55–e63.doi:10.2105/AJPH.2015.302664.
- Alderks CE. Trends in the use of methadone, buprenorphine, and extended-release naltrexone at substance abuse treatment facilities: 2003-2015 (update). Substance Abuse and Mental Health Services Administration, August 22, 2017.
- Hedegaard H, Miniño AM, Warner M. Drug overdose deaths in the United States, 1999-2017. Hyattsville, MD: National Center for Health Statistics Data Brief No. 329; 2019. Accessed Dec 2017. https://www.cdc.gov/nchs/products/databriefs/db329.htm
- Florence CS, Zhou C, Luo F, Xu L.The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Med Care. 2016;54:901–06.doi:10.1097/MLR.0000000000000625.
- Rhyan CN. The potential societal benefit of eliminating opioid overdoses, deaths, and substance use disorders exceeds $95 billion per year. Altarum/Center for Value in Health Care; November 16, 2017. Accessed 22 Apr 2020. https://altarum.org/sites/default/files/uploaded-publication-files/Research-Brief_Opioid-Epidemic-Economic-Burden.pdf
- Evans WN, Lieber E, Power P.How the reformulation of OxyContin ignited the heroin epidemic. Rev Econ Stat. 2019;101:1–15.doi:10.1162/rest_a_00755.
- Weiner J, Murphy SM, Behrends C.Expanding access to naloxone: a review of distribution strategies. Penn LDI/CHERISH Issue Brief; May 2019. Accessed 22 Apr 2020. https://ldi.upenn.edu/brief/expanding-access-naloxone-review-distribution-strategies
- Frank RG, Humphreys K, Pollack HA. Does naloxone availability increase opioid abuse? The case for skepticism. Health Affairs Blog; March 19, 2018. Accessed 22 Apr 2020. https://www.healthaffairs.org/do/10.1377/hblog20180316.599095/full
- Wakeland W, Nielsen A, Geissert P.Dynamic model of nonmedical opioid use trajectories and potential policy interventions. Am J Drug Alc Abuse. 2015;41:508–18.doi:10.3109/00952990.2015.1043435.
- Wakeland W, Nielsen A, Schmidt T, McCarty D, Webster L, Fitzgerald J, Haddox JD.Modeling the impact of simulated educational interventions in the use and abuse of pharmaceutical opioids in the United States: a report on initial efforts. Health Educ Behav. 2013;40:74S–86S.doi:10.1177/1090198113492767.
- Pitt AL, Humphreys K, Brandeau ML.Modeling health benefits and harms of public policy responses to the US opioid epidemic. Am J Pub Hlth. 2018;108:1394–400.doi:10.2105/AJPH.2018.304590.
- Chen Q, Larochelle MR, Weaver DT, Chhatwal J, Mueller PP, Mercaldo S, Wakeman SE, Freedberg KA, Raphel TJ, Knudsen AB, others. Prevention of prescription opioid misuse and projected overdose deaths in the United States. JAMA Open Network. 2019;2:e187621. doi:10.1001/jamanetworkopen.2018.7621.
- Jalali M, Botticelli M, Hwang R, Koh HK, McHugh RK. The opioid crisis: a contextual framework and call for systems science research. SSRN; 25 June 2019. Accessed 22 Apr 2020. https://www.ssrn.com/.
- Sharareh N, Sabounchi SS, McFarland M, Hess R. Evidence of modeling impact in development of policies for controlling the opioid epidemic and improving public health: a scoping review. Subst Abuse. 2019;13:1–10. 10.1177/1178221819866211.
- Sterman JD. Business dynamics: systems thinking and modeling for a complex world. Boston: McGraw-Hill; 2000.
- Homer J, Hirsch G.System dynamics modeling for public health: background and opportunities. Am J Public Hlth. 2006;96:452–58.doi:10.2105/AJPH.2005.062059.
- Homer JB.A system dynamics model of national cocaine prevalence. Sys Dyn Rev. 1993;9:49–78.doi:10.1002/sdr.4260090104.
- Hirsch G, Homer J, Tomoaia-Cotisel A, editors . System dynamics applications to health and health care. Sys Dyn Rev (virtual issue); January 2015. http://onlinelibrary.wiley.com/journal/10.1002/()1099-1727/homepage/VirtualIssuesPage.html
- U.S. Census Bureau. Statistical Abstract of the United States: 2012. 131st. Table 7: Resident population by sex and age: 1980 to 2010. Washington DC: US Census Bureau; 2011. https://www.census.gov/library/publications/2011/compendia/statab/131ed/population.html.
- U.S. Census Bureau. Projected 5-year age groups and sex composition: main projections series for the United States, 2017-2060. Table 3: Projected 5-year age groups and sex composition of the population. Washington DC: US Census Bureau; 2018. Accessed 22 Apr 2020. https://www.census.gov/data/tables/2017/demo/popproj/2017-summary-tables.html
- Pezalla EJ, Rosen D, Erensen JG, Haddox JD, Mayne TJ. Secular trends in opioid prescribing in the USA. J Pain Research. 2017;10:383–87.doi:10.2147/JPR.S129553.
- Centers for Disease Control and Prevention (CDC). U.S. opioid prescribing rate maps. Table 1: total number and rate of opioid prescriptions dispensed, United States, 2006-2017. 2018. Accessed 22 Apr 2020. https://www.cdc.gov/drugoverdose/maps/rxrate-maps.html
- Dasgupta N, Kramer ED, Zalman M-A, Jr S C, Smith MY, Haddox JD, Iv C W.Association between non-medical and prescriptive usage of opioids. Drug Alc Depend. 2006;82:135–42.doi:10.1016/j.drugalcdep.2005.08.019.
- U.S. Department of Justice, Drug Enforcement Administration (DOJ/DEA), Diversion Control Division. ARCOS retail drug summary reports. 2018. Accessed 22 Apr 2020. https://www.deadiversion.usdoj.gov/arcos/retail_drug_summary/
- US Centers for Medicare and Medicaid Services (CMS). Opioid morphine equivalent conversion factors. 2015. Accessed 22 Apr 2020. www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/Opioid-Morphine-EQ-Conversion-Factors-March-2015.pdf
- Jones CM, Christensen A, Gladden RM. Increases in prescription opioid injection abuse among treatment admissions in the United States, 2004-2013. Drug Alc Dependence. 2017;176:89–95.doi:10.1016/j.drugalcdep.2017.03.011.
- Substance Abuse and Mental Health Services Administration (SAMHSA). Treatment episode data set (annual). 2018. Accessed 22 Apr 2020. https://datafiles.samhsa.gov/info/browse-studies-nid3454
- Unick G, Rosenblum D, Mars S, Ciccarone D.The relationship between US heroin market dynamics and heroin-related overdose, 1992-2008. Addiction. 2014;109:1889–98.doi:10.1111/add.12664.
- U.S. Department of Justice, Drug Enforcement Administration (DEA). 2013 national level STRIDE price and purity data. DEA-DCW-DIR-068-15; Sept 2015. Accessed 22 Apr 2020. https://ndews.umd.edu/sites/ndews.umd.edu/files/pubs/2013%20National%20Level%20STRIDE%20Price%20and%20Purity%20Data.pdf
- U.S. Department of Justice, Drug Enforcement Administration (DEA). 2018 national drug threat assessment. DEA-DCT-DIR-032-18; Oct 2018. Accessed 22 Apr 2020. https://www.dea.gov/sites/default/files/2018-11/DIR-032-18%202018%20NDTA%20final%20low%20resolution.pdf
- National Forensic Laboratory Information System (NFLIS). NFLIS brief: fentanyl, 2001-2015. US DOJ/DEA; Mar 2017. Accessed 22 Apr 2020. https://www.nflis.deadiversion.usdoj.gov/DesktopModules/ReportDownloads/Reports/NFLISFentanylBrief2017.pdf
- National Forensic Laboratory Information System (NFLIS). NFLIS brief: fentanyl and fentanyl-related substances reported in NFLIS, 2015-2016. US DOJ/DEA; Oct 2017, updated March 2018. Accessed 22 Apr 2020. https://www.nflis.deadiversion.usdoj.gov/DesktopModules/ReportDownloads/Reports/11350_R2_NFLIS_Research_Brief_Fentanyl.pdf
- Hasegawa K, Espinola JA, Brown DFM, Camargo CA.Trends in U.S. emergency department visits for opioid overdose, 1993-2010. Pain Medicine. 2014;15:1765–70.doi:10.1111/pme.12461.
- Substance Abuse and Mental Health Services Administration (SAMHSA). Key substance use and mental health indicators in the United States: results from the 2018 national survey on drug use and health. Rockville, MD: Center for Behavioral Health Statistics and Quality, SAMHSA; 2019. HHS Pub. PEP19-5068, NSDUH Series H-54.
- Jones CM. Assessing the relationship between prescription opioid nonmedical use and heroin use. DHHS/OASPE, slide presentation; 2016. Accessed 22 Apr 2020. https://www.radars.org/system/events/RADARS%20System%202016%20Annual%20Meeting_Jones.pdf.tmp
- Muhuri PK, Gfroerer JC, Davies MC. Associations of nonmedical pain reliever use and initiation of heroin use in the United States. CBHSQ data review. Substance Abuse and Mental Health Services Administration; Aug 2013. Accessed 22 Apr 2020. https://www.samhsa.gov/data/sites/default/files/DR006/DR006/nonmedical-pain-reliever-use-2013.htm
- Compton WM, Volkow ND.Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alc Dependence. 2006;81:103–07.doi:10.1016/j.drugalcdep.2005.05.009.
- Kolodny A, Courtwright DT, Hwant CS, Kreiner P, Eadie JL, Clark TW, Alexander GC.The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Ann Rev Pub Health. 2015;36:559–74.doi:10.1146/annurev-publhealth-031914-122957.
- Substance Abuse and Mental Health Services Administration (SAMHSA). National survey on drug use and health (annual). 2018. Accessed 22 Apr 2020. https://datafiles.samhsa.gov/info/browse-studies-nid3454
- StreetRx.com. 2018. Accessed 22 Apr 2020. www.streetrx.com
- Bluelight.org. 2018. Accessed 22 Apr 2020. https://www.bluelight.org/xf/
- National Institute on Drug Abuse (NIDA). Overdose death rates 2018. Available at: https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates; see also: https://wonder.cdc.gov/
- Homer J. Reference guide for the opioid epidemic simulation model (version 2u). February 2020. Accessed 22 Apr 2020. https://pdxscholar.library.pdx.edu/sysc_fac/153/
- Johnston LD, Miech RA, O’Malley PM, Bachman JG, Schulenberg JE, Patrick ME. Monitoring the future national survey results on drug use, 1975-2018: overview, key findings on adolescent drug use. University of Michigan Institute for Social Research: Ann Arbor; 2019. Accessed 22 Apr 2020. https://eric.ed.gov/?id=ED594190
- Edlund MJ, Martin BC, Russo JE, Devries A, Braden JB, Sullivan MD.The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic non-cancer pain. Clin J Pain. 2014;30:557–64.doi:10.1097/AJP.0000000000000021.
- Reuter P. ed. Understanding the demand for illegal drugs. Vol. 124. Washington, DC: National Academies Press; 2010. https://www.nap.edu/catalog/12976/understanding-the-demand-for-illegal-drugs.
- National Institute on Drug Abuse (NIDA). Medications to treat opioid use disorder. 47pp; 2018. Accessed 22 Apr 2020. https://www.drugabuse.gov/publications/research-reports/medications-to-treat-opioid-addiction/overview
- Connery HS.Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harvard Rev Psychiatry. 2015;23:63–75.doi:10.1097/HRP.0000000000000075.
- Dasgupta N, Freifeld C, Brownstein JS, Menone CM, Surratt HL, Poppish L, Green JL, Lavonas EJ, Dart RC. Crowdsourcing black market prices for prescription opioids. J Med Internet Res. 2013;15:e178. doi:10.2196/jmir.2810.
- Rutkow L, Change H-Y, Daubresse M, Webster DW, Stuart EA, Alexander GC. Effect of Florida’s prescription drug monitoring program and pill mill laws on opioid prescribing and use. JAMA Intern Med. 2015;175:1642–49. doi:10.1001/jamainternmed.2015.3931.
- Lyapustina T, Rutkow L, Chang H-Y, Daubresse M, Ramji AF, Faul M, Stuart EA, Alexander GC. Effect of a “pill mill” law on opioid prescribing and utilization: the case of Texas. Drug Alc Dependence. 2016;159:190–97.
- Carlson RG, Nahhas RW, Martins SS, Daniulaityte R. Predictors of transition to heroin use among initially non-opioid dependent illicit pharmaceutical opioid users: a natural history study. Drug Alc Depend. 2016;160:127–34.doi:10.1016/j.drugalcdep.2015.12.026.
- Potter JS, Marino EN, Hillhouse MP, Nielsen S, Wiest K, Canamar CP, Martin JA, Ang A, Baker R, Saxon AJ. Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START). J Stud Alc Drugs. 2013;74:605–13. doi:10.15288/jsad.2013.74.605.
- Green JL, Bartelson BB, Le Lait MC, Roland CL, Masters ET, Mardekian J, Bailey JE, Dart RC. Medical outcomes associated with prescription opioid abuse via oral and non-oral routes of administration. Drug Alc Dependence. 2017;175:140–45.doi:10.1016/j.drugalcdep.2017.01.039.
- Hedegaard H, Miniño AM, Warner M. Drug overdose deaths in the United States, 1999-2018. Hyattsville, MD: National Center for Health Statistics Data Brief No. 356; Jan. 2020. https://www.cdc.gov/nchs/products/databriefs/db356.htm
- US News & World Report. Opioid overdose deaths down 5% from state’s peak in 2016. Associated Press, Wire Service Content; Feb. 12, 2020. https://www.usnews.com/news/best-states/massachusetts/articles/2020-02-12/opioid-overdose-deaths-down-5-from-states-peak-in-2016
- Mack KA, Jones CM, Ballesteros MF. Illicit drug use, illicit drug use disorders, and drug overdose deaths in metropolitan and nonmetropolitan areas—United States. Morbidity Mortality Weekly Rep; 2017. 66:1–12. https://www.cdc.gov/mmwr/volumes/66/ss/ss6619a1.htm.
- Adams JM. Increasing naloxone awareness and use: the role of health care practitioners. JAMA (Online); April 5 2018. E1–E2. doi:10.1001/jama.2018.4867.
- Lynn RR, Galinkin JL.Naloxone dosage for opioid reversal: current evidence and clinical implications. Therap Adv in Drug Saf. 2018;9:63–88.doi:10.1177/2042098617744161.
- Wheeler E, Jones TS, Gilbert MK, Davidson PJ.Opioid overdose prevention programs providing naloxone to laypersons—United States, 2014. MMWR. 2015;64:631–34.
- Weiner J, Murphy SM, Behrends C. Expanding access to naloxone: a review of distribution strategies. U Penn: LDI/CHERISH Issue Brief, 6 pp; 2019. Accessed 22 Apr 2020. https://ldi.upenn.edu/brief/expanding-access-naloxone-review-distribution-strategies
- Volkow ND, Frieden TR, Hyde PS, Cha SS.Medication-assisted therapies—tackling the opioid-overdose epidemic. N Engl J Med. 2014;370:2063–66.doi:10.1056/NEJMp1402780.
- Hinde J, Hayes J, Mark T, Bernstein S, Karon SL. State and local policy levers for increasing treatment and recovery capacity to address the opioid epidemic: final report. RTI International: Research Triangle Park, NC. For ASPE/DHHS. Sept 29, 2017. Accessed 22 Apr 2020. https://aspe.hhs.gov/basic-report/state-and-local-policy-levers-increasing-treatment-and-recovery-capacity-address-opioid-epidemic-final-report
- Orgera K, Tolbert J. The opioid epidemic and Medicaid’s role in facilitating access to treatment. Kaiser Family Foundation, May 2019. Accessed 22 Apr 2020. https://www.kff.org/medicaid/issue-brief/the-opioid-epidemic-and-medicaids-role-in-facilitating-access-to-treatment/
- Hernandez EJM. Increasing access to medication-assisted treatment for opioid use disorders: estimating costs, supply, and the effects of insurance expansions. 2017. PhD Dissertation, Pardee RAND Graduate School. https://www.rand.org/pubs/rgs_dissertations/RGSD404.html
- Wakeland W, Homer J. Addressing parameter uncertainty in SD models with fit-to-history and Monte Carlo sensitivity methods and with application to an opioid epidemic model. Proc. 38th Intl Conf of the Syst Dyn Soc, Bergen, Norway; 2020. Accessed 22 Apr 2020. https://works.bepress.com/wayne_wakeland/121/
- Brunt T. Drug checking as a harm reduction tool for recreational drug users: opportunities and challenges. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA); Oct 30, 2017. Accessed 22 Apr 2020. http://www.emcdda.europa.eu/system/files/attachments/6339/EuropeanResponsesGuide2017_BackgroundPaper-Drug-checking-harm-reduction_0.pdf